ArticleRomanian journal of ophthalmology
Bilateral neurotrophic keratitis associated with Gilteritinib therapy in a patient with acute myeloid leukemia: a case report.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We report the first documented case of bilateral neurotrophic keratitis potentially associated with Gilteritinib therapy. Case Presentation: A 52-year-old male patient presented with bilateral blurred vision and photophobia due to neurotrophic keratitis, which developed after two years of treatment with Gilteritinib - a second-generation tyrosine kinase inhibitor (TKI) used for relapsed or refractory acute myeloid leukemia (AML) with a confirmed FMS-like tyrosine kinase 3 (FLT3) mutation. His best-corrected visual acuity (BCVA) was 20/100 in the right eye and 20/40 in the left eye. Biomicroscopic examination revealed persistent epithelial defects, reduced corneal sensitivity, and no tear-film abnormalities or eyelid pathology. Gilteritinib was discontinued in consultation with the hematology team, and topical insulin with preservative-free lubricants was initiated. Within one week, the epithelial defects had healed, and at one month, visual acuity had improved to 20/20 in the left eye and 20/32 in the right eye, with residual central leukoma. Discussion: Neurotrophic keratitis is a rare corneal disorder caused by impaired innervation and defective epithelial healing. After exclusion of all known etiologies, prolonged Gilteritinib therapy was considered the most likely cause in our patient, possibly due to off-target effects on pathways involved in corneal nerve and epithelial homeostasis. Treatment with artificial tears and topical insulin led to favorable epithelial healing, underscoring the need for awareness of potential ocular surface toxicity with newer tyrosine kinase inhibitors. Conclusion: This case highlights potential ocular neurotoxicity associated with Gilteritinib, a targeted therapy not previously linked to corneal nerve dysfunction. Increased clinical awareness is recommended for ophthalmologists and hematologists managing patients with FLT3-mutated AML who are receiving targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.